Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:43 PM
Ignite Modification Date:
2025-12-24 @ 4:43 PM
NCT ID:
NCT02859766
Eligibility Criteria:
Inclusion Criteria:
-Presence of active subfoveal and/or juxtafoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Exclusion Criteria:
* History of or active periocular, ocular, or intraocular infection.
* Previous use of verteporfin photodynamic therapy (PDT) or any ocular anti-angiogenic therapy (eg, aflibercept, bevacizumab, ranibizumab, pegaptanib), approved or investigational, for the treatment of neovascular AMD or previous therapeutic radiation in the region.
* Prior use of ocular anti-VEGF agents for neovascular eye diseases other than AMD.
* Macular hemorrhage that involves the center of fovea in the study eye.
* Any prior or current systemic or ocular treatment (including surgery) for neovascular AMD in the study eye.
* Treatment with ocular corticosteroid injections or implants within 6 months in the study eye.
* History or evidence of eye surgery: Pars plana vitrectomy, Submacular surgery or other surgical interventions for AMD, Incisional glaucoma surgery or Cataract or refractive surgery within the last 3 months.
* AMD in the non-study eye that requires anti-VEGF treatment.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
50 Years
Study:
NCT02859766
Study Brief:
Protocol Section:
NCT02859766